Orphan Drug Manufacturers To Discuss Easier Drug Access To Rare Disease Patients Globally, 9-11 April 2013, Washington DCMain Category: Conferences
Article Date: 14 Jan 2013
Though making headway in developed orphan drug markets such as US, Europe, Australia and some countries in Asia, rare disease patients in the rest of the world have yet to see the light of day.
Over 400 biotechs, pharma, research institutions and regulators will gather at the World Orphan Drug Congress USA in Washington DC on April 9-11, 2013. Key speakers include Flemming Ornskov, Shire's Chief Executive Designate; Charles Johnson, Vice President, Respiratory Medicine from Vertex Pharmaceuticals; Jimmy Lin, Founder & President of the Rare Genomics Institute; and, Martine Zimmerman, Executive Director, Global Regulatory Affairs from Alexion Pharmaceuticals.
This conference and expo provides a platform for key movers and shakers of the orphan drug industry to come together and discover partnerships and collaborations to expedite orphan drugs to patients globally.
Various facets to highlight key needs of the industry are as follows:
Marketing Director Terrapinn
caroline.hornby (at) terrapinn.com
+1 646 619 1792
Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today